Research programme: noninvasive proprietary formulation therapeutics - Neurelis
Latest Information Update: 20 Sep 2024
Price :
$50 *
At a glance
- Originator Neurelis
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders; Epilepsy
Most Recent Events
- 26 Jul 2024 Preclinical trials in CNS disorders in USA (unspecified route) prior to July 2024 (Neurelis pipeline, July 2024)
- 26 Jul 2024 Preclinical trials in Epilepsy in USA (unspecified route) prior to July 2024 (Neurelis pipeline, July 2024)